Showing 2971-2980 of 3448 results for "".
- FDA Clears Candela's Vbeam 595 nm Pulsed Dye Laser for the Treatment of Port Wine Stains and Hemangiomas in the Pediatric Populationhttps://practicaldermatology.com/news/fda-clears-vbeam-595-nm-pulsed-dye-laser-for-the-treatment-of-port-wine-stains-and-hemangiomas-in-the-pediatric-population/2461824/The U.S Food and Drug Administration has cleared candela’s Vbeam family of 595 nm wavelength pulsed dye lasers (PDL) to treat cutaneous capillary malformations, and infantile hemangiomas (IH)/congenital hemangiomas in the pediatric population (from birth – 21 years of age).
- Oro Health, Dermago Unveil Consumer Version of its AI-powered Dermatology Assessment and Recommendation Toolhttps://practicaldermatology.com/news/oro-health-dermago-unveil-consumer-version-of-its-ai-powered-dermatology-assessment-and-recommendation-tool/2461822/Oro Health and Dermago are unveiling the public version of DermSmart, a tool designed to classify skin types and minor skin conditions. This new AI-driven version offers patients the ability to upload pictures of their skin condition, ask questions and interact with the tool i
- Bimekizumab Update: FDA Still Reviewing UCB's BLAhttps://practicaldermatology.com/news/bimekizumab-update-fda-still-reviewing-ucbs-bla/2461813/The U.S. Food & Drug Administration (FDA) is still reviewing UCB’s Biologics License Application (BLA) for bimekizumab for moderate to severe plaque psoriasis, UCB reports. UCB previously
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to
- Take That, Melanoma: Universal Cancer Vaccine Boosts Overall Survivalhttps://practicaldermatology.com/news/take-that-melanoma-universal-cancer-vaccine-boosts-overall-survival/2461790/Ultimovacs’ UV1 universal cancer vaccine boosted overall survival in malignant melanoma, according to a three-year update from a Phase I clinical trial. UV1 is a universal cancer vaccine designed to induce a specific T cell response against telomerase. The U.S. Food and Drug Admin
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long
- Belotero Balance (+) Restores Volume to Under-eye Hollowshttps://practicaldermatology.com/news/belotero-balance-restores-volume-to-under-eye-hollows/2461782/Belotero Balance® (+) corrects volume loss in the infraorbital hollow area, according to new data from Merz Aesthetics. Merz Aesthetics will submit these data as part of a supplemental Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) this
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr